Prokarium is biopharmaceutical company leading the oncology field of microbial immunotherapy.
Prokarium has raised $30.0M in total funding. The most recent round was Series B. The last funding was announced in February 2023.
Prokarium's investors include Wellcome Trust, Korea Investment Partners, Innovate UK, The Future Fund, SynbiCITE.
Prokarium is headquartered in London, United Kingdom.
Prokarium is biopharmaceutical company leading the oncology field of microbial immunotherapy.
Prokarium is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prokarium — Funding & Investors." VCBacked, February 9, 2023, https://www.vcbacked.co/company/prokarium. Accessed November 13, 2026.
VCBacked. (2023). Prokarium — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/prokarium
{{cite web |title=Prokarium — Funding & Investors |url=https://www.vcbacked.co/company/prokarium |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Prokarium? Request a listing update